AIM
GBT

Advantage Investment Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Advantage Investment Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$5K Hold
100
– – ﹤0.01% 774
2019
Q2 		$5K Buy
+100
New +$5.75K ﹤0.01% 777

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Advantage Investment Management's GBT Position: Q3 2019 in Review

Advantage Investment Management held its Global Blood Therapeutics, Inc. (GBT) position steady in Q3 2019 at 100 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #774.

Advantage Investment Management first reported a position in GBT in Q2 2019 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold GBT as of Q3 2019.

  • Advantage Investment Management held 100 shares of Global Blood Therapeutics, Inc. worth $5K as of Q3 2019.
  • Advantage Investment Management left its Global Blood Therapeutics, Inc. share count unchanged in Q3 2019.
  • Global Blood Therapeutics, Inc. made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #774 holding.
  • Advantage Investment Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.